Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

JACC Heart Fail. 2024 Jun;12(6):1123-1125. doi: 10.1016/j.jchf.2024.03.009. Epub 2024 Apr 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Benzylamines
  • Cardiomyopathy, Hypertrophic* / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome
  • Uracil / analogs & derivatives

Substances

  • MYK-461
  • Benzylamines
  • Uracil